Novimmune Sells Gamifant And IO Assets To Sobi
Executive Summary
Swiss biotech Novimmune SA creates newco around Gamifant emapalumab and other immuno-oncology assets and then sells it to Sobi for CHF515m ($519.2m).
You may also be interested in...
Sobi Reaps Benefits From Acquisitions, Commercial Focus
Sweden’s mid-sized pharmaceutical company, Swedish Orphan Biovitrum, has expanded into hematology and strengthened its immunology business, growing its top and bottom lines in 2019.
Sobi Targets Thrombocytopenia In $915m Swoop For Dova
The Swedish group has got hold of the ITP and CLD drug Doptelet, widening its hematology business beyond hemophilia.
AstraZeneca Buys Priority Review Voucher With Two Big Filings On The Horizon
AstraZeneca paid $95m to Swedish Orphan Biovitrum for the voucher, which it could use to expedite the FDA review of roxadustat or trastuzumab deruxtecan.